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Rationale: Idiopathic pulmonaryfibrosis (IPF) is characterizedbypro-
gressive dyspnea, impaired gas exchange, and ultimate mortality.
Objectives: To test the hypothesis that maximal oxygen uptake
during cardiopulmonary exercise testing at baseline and with
short-term longitudinal measures would predict mortality in
patients with idiopathic pulmonary fibrosis.
Methods: Data from 117 patients with IPF and longitudinal cardio-
pulmonary exercise tests were examined retrospectively. Survival
was calculated from the date of the first cardiopulmonary exercise
test.
Measurements and Main Results: Patients with baseline maximal
oxygen uptake less than 8.3 ml/kg/min had an increased risk of
death (n5 8; hazard ratio, 3.24; 95%confidence interval, 1.10–9.56;
P 5 0.03) after adjusting for age, gender, smoking status, baseline
forced vital capacity, and baseline diffusion capacity for carbon
monoxide. We were unable to define a unit change in maximal
oxygen uptake that predicted survival in our cohort.
Conclusions:Weconclude that a thresholdmaximaloxygenuptakeof
8.3 ml/kg/min during cardiopulmonary exercise testing at baseline
adds prognostic information for patients with IPF.
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Idiopathic pulmonary fibrosis (IPF) is a disease of unknown
etiology characterized by progressive dyspnea and ultimate
mortality (1). Mean survival from time of diagnosis to death is
3 years (1).However, the disease course is variable: some patients
progress rapidly and others remain stable for many years (2).
There is no effective treatment and many patients, if eligible, are
referred for lung transplantation. Identification of surrogate
short-term measures of mortality is critical to the management
and study of patients with IPF.
Several factors have been identified that predict poor survival
in patients with IPF, including age, sex, smoking history, diffusion
capacity for carbonmonoxide (DLCO), FVC, degree of fibrosis on
high-resolution computerized tomography of the chest, and
number of fibroblastic foci on histopathology (3–11). Longitudi-
nal changes in FVC or DLCO have been found to have important
prognostic value.Adecrease in FVCof at least 10%orDLCOof at
least 15% over 6 or 12 months is associated with decreased
survival (10–15).
Gas exchange worsens with exercise in IPF (1, 16, 17). Several
studies have examined this feature using either cardiopulmonary
exercise tests (CPET) or the 6-minute-walk test (6MWT). A
decrease in PaO2 duringCPET in patients with IPF contributes up
to 10.5% of the total clinical, radiographic, and physiologic
(CRP) score (5) used to estimate prognosis in IPF. Desaturation
during CPET has been shown to predict mortality in some (16)
but not all (18, 19) studies. Desaturation below 88% during
6MWT is amore consistentmarker of increased risk formortality
(7, 9, 10), whereas shorter walk distance is less predictive (15).
Longitudinal change in 6MWTdata predicts mortality in patients
who do not desaturate less than 88% at baseline (15).
Patients with IPF have impaired ventilatory and cardiovas-
cular responses to exercise (20) due to multiple abnormalities,
including low tidal volume; a failure to decrease ventilatory
dead space; a rapid, shallow breathing pattern; impaired gas
exchange due to interstitial fibrosis; pulmonary hypertension;
ventilation/perfusion mismatching; and low mixed venous O2.
_VO2max is an integrated measure of cardiovascular, respira-
tory, and neuromuscular function (21). In prior studies of
patients with interstitial lung disease, _VO2max correlated poorly
with measures of lung volume, suggesting that it more accu-
rately reflects derangements in hemodynamics as well as
ventilation during exercise (20). Although change in FVC is
a good surrogate for subsequent mortality, it is imperfect as
some patients die without a 10% decline in FVC, whereas
others can live for prolonged periods even after a 10% decline
in FVC (2, 22). Therefore we chose to examine longitudinal
change in _VO2max a priori because it is an integrated measure
of cardiovascular, respiratory, and neuromuscular function (21).
We tested the hypothesis that a decrease in _VO2max during
baseline and short-term longitudinal CPETs predicts mortality
in patients with IPF.
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Prognosis in idiopathic pulmonary fibrosis (IPF) is poor.
Predicting prognosis by examining exercise performance
with the six-minute-walk test has led to conflicting results.
What This Study Adds to the Field
This study shows that _VO2max predicts mortality in patients
with IPF. Patients with _VO2max less than 8.3 ml/kg/min at
baseline had an increased risk of death.
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This is a retrospective analysis of 117 patients in the University of
Michigan Specialized Center of in the Pathobiology of Fibrotic Lung
DiseaseDatabase. Patients in this database were referred for enrollment
in study protocols for suspected IPF based on typical symptoms,
physiologic findings, and radiographic findings (1). Patients with
a high-resolution computerized tomography scan showing a definite
pattern of usual interstitial pneumonitis (23) were not required to
undergo surgical lung biopsy (n5 42) (24, 25). Patients with underlying
connective tissue disease, occupational or environmental exposures, or
histopathologic pattern on surgical lung biopsy other than usual in-
terstitial pneumonitis were excluded. Patients were treated with varied
regimens, including no therapy, immunosuppression (prednisone 6
azathioprine or cyclophosphamide), colchicine, and experimental pro-
tocols. The lack of a standardized treatment regimen prevented an
analysis of the data based on therapy. Approval for the use of these data
was provided by our Institutional Review Board. Subgroups of these
patients have been previously described (7, 15, 26).
Pulmonary Function, 6-Minute Walk, and Cardiopulmonary
Exercise Tests
Pulmonary function and exercise tests, including FVC, DLCO, 6MWT,
and CPET, were performed as described (7, 18). Desaturation during
a 6MWT was defined a priori as less than 88% based on published data
(7).
Statistical Analysis
The date of the first CPET was used as the start date for survival
analysis. Death date was supplemented by searching the Social Security
Death Index (27); patients not listed in this index were censored
3 months prior to the analysis date to account for potential lags in
reporting. Multivariate Cox proportional hazard models (28) adjusted
for age, sex, baseline forced vital capacity percent predicted, baseline
DLCO percent predicted, and smoking status were constructed for po-
tential _VO2max thresholds ranging from 4.4 ml/kg/min to 25.1 ml/kg/min,
in increments of 0.3 ml/kg/min. Resulting hazard ratios were plotted
against _VO2max to determine if a threshold _VO2max could be identified
that correlated with increased risk of mortality. Similar secondary
analyses were performed on resting PaO2. Baseline characteristics be-
tween patients with _VO2max above and below the thresholds were
compared using t tests (29) for continuous measures and chi-square
(30) tests for categorical measures. Data are expressed as mean 6
standard deviation (SD) or frequency (%). In secondary analyses,
index of concordance (31) was used compare the _VO2max threshold,
desaturation less than 88% during a 6MWT, and resting PaO2 to
determine which was the strongest predictor of survival. Survival
between patients with baseline _VO2max above and below thresholds
was examined with unadjusted Kaplan Meier survival curves (32) and
log-rank tests (33, 34). Multivariate Cox proportional hazard models
studied the predictive value of the _VO2max threshold adjusted for age,
gender, smoking status, baseline FVC percent predicted (FVC%), and
baseline DLCO percent predicted (DLCO%). Statistical significance was
set at P 5 0.05. Statistical analysis was performed with R software
(http://www.r-project.org/index.html) and SPSS (version 14.0; SPSS
Inc., Chicago, IL).
RESULTS
Data from 117 patients with at least two cardiopulmonary
exercise tests were analyzed. Seventy-five (64%) patients were
diagnosed with a surgical lung biopsy. Patients who did not
undergo a lung biopsy were significantly older (66.73 6 8.50 vs.
63.076 8.23 y, P5 0.024) but otherwise not different than those
with a lung biopsy (data not shown).
We explored the predictive value of _VO2max on survival.
_VO2max did not predict survival when examined as a continuous
variable (hazard ratio [HR], 0.969; 95% confidence interval
[CI], 0.88–1.07; P 5 0.55). Exploratory analyses revealed
a threshold _VO2max of 8.3 ml/min/kg that was associated with
an increased risk of subsequent mortality (Figure 1). This
threshold effectively captures patients with a higher risk of
mortality and discriminates these patients from those with
a lower risk of mortality.
Demographic data and baseline physiologic data for patients
with an initial _VO2max above or below 8.3 ml/min/kg are
presented in Table 1. Patients whose baseline _VO2max was below
threshold were more often female (P 5 0.04), had significantly
lower FVC% (P 5 0.01) and DLCO% (P 5 0.006), shorter 6-
minutewalk distance (P5 0.002), and significantly lower exercise
capacity during baseline CPET compared with those with base-
line _VO2max above threshold (Table 1). Surprisingly, not all
patients with _VO2max below threshold at baseline desaturated
during a baseline 6MWT.
Multivariate relationships between _VO2max and baseline de-
mographic and pulmonary function variables were explored
(Table 2). In multivariate linear regression models, age, male
gender, history of smoking, and baseline FVC were predictors of
_VO2max. A linear predictor incorporating these variables signif-
icantly predicted whether a patient’s baseline _VO2max would be
below threshold (Table 3). With this model, patients who are
younger, male, never smokers, with higher FVC% and DLCO%
are more likely to have a _VO2max above 8.3 ml/min/kg, and thus
are predicted to have overall improved survival than older,
female, ever smokers with lower FVC% and DLCO%.
Survival inpatientswithbaseline _VO2maxbelowthe8.3ml/kg/min
threshold was lower than that of patients above the threshold
over time (log rank P , 0.001, Figure 2). This difference was
maintained in multivariate Cox proportional hazard survival
models adjusting for patient age, smoking status, male sex,
baseline FVC%, and baseline DLCO% (HR for being below
Figure 1. Determination of a _VO2max threshold of 8.3 ml/kg/min.
MultivariateCoxproportionalhazardmodels adjustedfor age, sex,baseline
FVC percent predicted, baseline diffusion capacity of carbon monoxide
percent predicted, and smoking status were constructed for potential
_VO2max thresholds ranging from 4.4 ml/kg/min to 25.1 ml/kg/min, in
increments of 0.3 ml/kg/min. The vertical axis gives hazard ratios compar-
ing risk of patients aboveandbelow the corresponding threshold along the
horizontal axis. A threshold baseline _VO2max of 8.3 ml/min/kg was
determined (dashed line).
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threshold, 3.24; 95% CI, 1.10–9.56; P 5 0.03) (Figure 3 and
Table 4).
In the majority of patients studied, _VO2max did not change
between baseline and 6 months (n 5 99). Of the 109 patients
with _VO2max above threshold at baseline, 5 had a further
decline in _VO2max below the threshold with longitudinal
measures. However, we were unable to define a unit change
in _VO2max that predicted survival in our cohort (data not
shown).
Prior studies have shown that resting PaO2 predicts survival
in IPF. In secondary analyses, resting PaO2 was a significant
predictor of mortality (HR, 0.934; 95% CI, 0.88–0.99; P 5 0.02),
when adjusted for age, sex, smoking status, and baseline FVC%
and DLCO%. A clear threshold for resting PaO2 could not be
determined (data not shown). An adjusted multivariate Cox
model with the _VO2max threshold (HR, 2.66; 95% CI, 0.74–9.5;
P 5 0.13) and resting PaO2 (HR, 0.95; 95% CI, 0.89–1.00; P 5
0.09) did not show significance of either predictor. When the
_VO2max threshold, resting PaO2, and desaturation below 88%
during a 6MWT were included in an adjusted Cox model, the
_VO2max threshold was a significant predictor of mortality (HR,
3.48; 95% CI, 1.16–10.43; P 5 0.03), whereas desaturation less
than 88% was not (HR, 1.49; 95% CI, 0.617–3.62; P 5 0.37).
Index of concordance analysis demonstrated that the _VO2max
threshold is a more robust predictor of survival than resting
PaO2 or desaturation less than 88% during a 6MWT (Table 5).
DISCUSSION
In this study, we examined the relationship between maximal
oxygen uptake during cardiopulmonary exercise testing and
mortality. We hypothesized that _VO2max measured during
cardiopulmonary exercise testing predicts mortality in patients
with IPF. We found that _VO2max examined as a continuous
variable does not predict mortality in IPF. However, baseline
threshold _VO2max of 8.3 ml/kg/min predicts mortality in these
patients. This threshold is a robust predictor of survival when
TABLE 2. MULTIVARIATE LINEAR REGRESSION MODEL
DETECTING ASSOCIATIONS WITH _VO2max
b SE P Value
Age, yr 20.23 0.04 ,0.001
Male sex 2.53 0.79 0.002
Ever smoker 21.61 0.72 0.028
Baseline FVC% 0.82 0.28 0.004
Baseline DLCO% 0.30 0.31 0.332
Definition of abbreviations: DLCO% 5 diffusion capacity for carbon monoxide
percent predicted; FVC% 5 forced vital capacity percent predicted; SE 5
standard error; _VO2max 5 maximal oxygen consumption during cardiopulmo-
nary exercise testing.
n 5 103.
TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS
WITH BASELINE _VO2max ABOVE OR BELOW THE
8.3 ml/kg/min THRESHOLD
Above Threshold Below Threshold P Value
n 109 8
Age, yr 64.0 6 8.4 69.1 6 8.6 0.10
Sex 0.044
Male 78 (78.8%) 3 (37.5%)
Female 31 (31.3%) 5 (62.5%)
Diagnosed with lung biopsy 70 (70.7%) 5 (62.5%) 0.92
Smokers 0.30
Never smokers 28 (28.3%) 4 (50%)
Former smokers 76 (76.7%) 4 (50%)
Current smokers 5 (5.0%) 0
Pack-years 39.2 6 24.9 42.0 6 44.4 0.84
Spirometry at baseline
FVC, L 2.8 6 0.9 1.8 6 0.6 0.002
FVC% 69.0 6 17.8 53.0 6 9.6 0.01
DLCO, ml/min/mm Hg 12.3 6 4.4 7.1 6 1.3 0.002
DLCO% 47.8 6 14.9 31.9 6 7.7 0.006
Exercise at baseline
Exercise PaO2 67.4 6 15.0 59.4 6 12.6 0.25
Exercise Aa gradient 41.0 6 14.7 42.2 6 13.3 0.85
Exercise saturation 89.5 6 4.9 88.0 6 5.7 0.41
Minutes of exercise 7.4 6 1.9 4.2 6 1.5 ,0.001
Work, W 95.2 6 35.0 40.0 6 11.6 ,0.001
_VO2max, ml/kg/min 14.0 6 4.2 6.9 6 1.4 ,0.001
Exercise gas exchange score 12.4 6 9.8 20.0 6 14.2 0.04
6MWT at baseline
Desaturation , 88% 38 (38.4%) 5 (62.5%) 0.12
Distance, ft 1,116.6 6 456.0 582.2 6 386.1 0.002
Definition of abbreviations: Aa gradient 5 alveolar-arterial gradient; DLCO% 5
diffusion capacity for carbon monoxide percent predicted; FVC% 5 forced vital
capacity percent predicted; _VO2max 5 maximal oxygen consumption during
cardiopulmonary exercise testing; 6MWT 5 6-min-walk test.
Data are shown as mean 6 standard deviation (SD) or frequency (%).
TABLE 3. LOGISTIC REGRESSION MODEL OF PREDICTORS OF
_VO2max , 8.3 ml/kg/min
OR 95% CI P Value
Linear predictor 0.57 0.37–0.87 0.01
Linear predictor 5 20.232(age) 1 2.53(male gender) 2 1.6(ever smoker) 1
0.82(FVC%) 1 0.30(DLCO%).
Definition of abbreviations: CI 5 confidence interval; DLCO% 5 baseline
diffusion capacity for carbon monoxide percent predicted; FVC% 5 baseline
forced vital capacity percent predicted; OR 5 odds ratio; _VO2max 5 maximal
oxygen consumption during cardiopulmonary exercise testing.
n 5 103.
Figure 2. Unadjusted Kaplan-Meier survival curves for patients whose
baseline _VO2max was greater than 8.3 ml/min/kg (Above Threshold,
n 5 99) or less than 8.3 ml/min/kg (Below Threshold, n 5 8). Survival
time was calculated from the date of the first cardiopulmonary exercise
test.
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compared with desaturation less than 88% during a 6MWT and
resting PaO2. Demographic and pulmonary function data can
be used to estimate whether _VO2max is above or below the 8.3ml/
kg/min threshold.
We found a threshold baseline _VO2max less than 8.3 ml/kg/
min predicts mortality in patients with IPF. A similar threshold
value has not been reported in fibrotic lung disease. In a study
of 86 patients with primary pulmonary hypertension, Wensel
and colleagues (35) found a _VO2max threshold of 10.4 ml/kg/min
predicts mortality. Various measures of exercise capacity have
been examined for their ability to predict survival in IPF. A
CRP score was developed by Watters and colleagues (36) as
a tool to assess and follow patients’ clinical impairment from
IPF. The score used an exercise gas exchange score, which
assigned points based on change in saturation during exercise,
change in VO2, and predicted _VO2max. The maximum points
attributable to exercise gas exchange in the CRP score was 30,
greater than the radiological, symptoms, and pulmonary func-
tion components of the score, reflecting the importance of
exercise gas exchange in clinical impairment in IPF. More
recently, Miki and colleagues (37) calculated the change in
PaO2 per change in VO2 during CPET (DPaO2/DVO2 or PaO2
slope) and found this relationship to predict mortality in
patients with IPF. However, not all studies show that CPET
measurements of gas exchange predict survival (18, 19). Studies
that have used multistep scores (CRP score) or slope calcu-
lations (PaO2 slope) to define the risk of mortality attributable to
exercise gas exchange in IPF may be too cumbersome for
routine use outside of clinical trials. Our data suggest that
a simple threshold for _VO2max of 8.3 ml/kg/min predicts
mortality in patients with IPF, without the need for lengthy
calculations.
Several authors have examined the prognostic value of the
6MWTor other walk tests in IPF.Desaturation during 6MWT (7,
9), distance walked (9), and progressive impairment in longitu-
dinal 6MWTs (15) have been found to predict mortality in IPF.
One criticismof the 6MWT is that it is a patient-driven, symptom-
and effort-limited test. This may explain the controversy in the
literature about whether distance walked or desaturation is
a better predictor of mortality. It may also explain why not all
patients in this studywith a baseline _VO2max below threshold had
desaturation during 6MWT: these patientsmight not havewalked
sufficiently fast or far enough to produce desaturation.
Using index of concordance techniques, we compared the
ability of desaturation less than 88% during a 6MWT and the
_VO2max threshold to predict mortality in IPF. Despite the small
number of patients with _VO2max below threshold at baseline, this
variable was a stronger predictor than desaturation less than 88%
in our cohort in multivariate Cox models. The _VO2max threshold
is also more robust than resting PaO2 and desaturation less than
88% during a 6MWT in concordance analyses.
We were unable to identify a unit change in _VO2max per
time that predicts survival in short-term follow-up. This may be
due to the small number of patients who had a decline in
_VO2max during the follow-up period. This could suggest that
_VO2max is more stable over time compared with other meas-
ures, such as FVC or DLCO. It could also reflect a selection bias
in that as patients became sicker they may have declined
exercise testing but still been able to perform pulmonary
function testing. Further prospectively collected data are
needed to explore the changes in _VO2max over time and their
impact on survival.
There are several limitations to this study. Patients in this
study were not evaluated for the presence of pulmonary hyper-
tension. Pulmonary hypertension has been shown to be an
important predictor of mortality in IPF (38–40), although its
presence does not universally portend a poor outcome (40).
Figure 3. Cox proportional hazard survival curves for patients with
baseline _VO2max greater than 8.3 ml/kg/min (solid line) and less than
8.3 ml/kg/min (dashed line) adjusted for age, sex, smoking status,
baseline FVC percent predicted, and baseline DLCO percent predicted.
Survival time was calculated from the date of the first cardiopulmonary
exercise test.
TABLE 4. MULTIVARIATE COX PROPORTIONAL HAZARD
SURVIVAL MODEL ASSESSING THE PREDICTIVE VALUE OF
_VO2max , 8.3 ml/min/kg
HR 95%CI P Value
_VO2max below threshold 3.24 1.10–9.56 0.03
Age, yr 1.04 1.00–1.08 0.08
Male sex 1.29 0.62–2.69 0.50
Ever smoker 1.33 0.71–2.48 0.37
Baseline FVC% 0.93 0.72–1.21 0.58
Baseline DLCO% 0.66 0.49–0.90 0.01
Definition of abbreviations: CI 5 confidence interval; DLCO% 5 diffusion
capacity for carbon monoxide percent predicted; FVC% 5 forced vital capacity
percent predicted; HR 5 hazard ratio; _VO2max 5 maximal oxygen consumption
during cardiopulmonary exercise testing.
n 5 103.
TABLE 5. INDEX OF CONCORDANCE ANALYSIS COMPARING
THE STRENGTH OF _VO2max , 8.3 ml/kg/min, DESATURATION ,
88% DURING A 6-MINUTE WALK TEST, AND RESTING PaO2
AS PREDICTORS OF SURVIVAL IN IDIOPATHIC PULMONARY
FIBROSIS
Model Ratio Concordance
_VO2max , 8.3 ml/kg/min 0.716 2342.5
Desaturation , 88% 0.708 2316.5
Resting PaO2 0.702 2322.7
Definition of abbreviations: DLCO% 5 diffusion capacity for carbon monoxide
percent predicted; FVC% 5 forced vital capacity percent predicted; PaO2 5
arterial partial pressure of oxygen; _VO2max 5 maximal oxygen consumption
during cardiopulmonary exercise testing; 6MWT 5 6-min-walk test.
Covariates in each model were: age, male sex, smoking status, FVC%, and
DLCO%. Number of paired observations: 3,271.
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Patients included in this study were enrolled in a number of
treatment protocols; the varied nature of the protocols prevents
an analysis of the data based on therapy. However, none of the
therapies in use in these protocols has been found to slow, halt, or
reverse pulmonary fibrosis in this population, and prior analyses
of the effects of therapy on this population have shown no benefit
(7, 18, 41). In our cohort of 117 patients, 8 had a baseline _VO2max
below threshold and 5 had a decrease in _VO2max to below
threshold over the course of follow-up, yet 46% of the patients
died during follow-up. Other measures that demonstrate signif-
icant change over time, such as serial measures of FVC%,may be
more sensitive predictors of mortality in this population. Alter-
nately, deaths could have been due to acute exacerbations of IPF
or other acute events, which we did not measure.
In this study, we examined the prognostic value of CPET in
IPF. A baseline _VO2max less than 8.3 ml/kg/min threshold was
identified, below which the risk of death was greatly increased.
This study provides an easy-to-use threshold for _VO2max for
patients with IPF that predicts an increased risk of death. An
unexpected finding was that not all patients with _VO2max below
threshold desaturated during a 6MWT. Direct comparison of
baseline _VO2max less than 8.3 ml/kg/min during CPET and
desaturation less than 88% during a 6MWT shows that the
_VO2max threshold is a better predictor of survival in IPF. CPET
and the 8.3 ml/kg/min threshold provide additional information
to clinicians and their patients to help guide therapeutic decisions
in IPF.
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